In a Phase 2 clinical trial evaluating Inovio Pharmaceuticals' VGX-3100 as a treatment for biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3), the cancer immunotherapy candidate achieved its primary endpoint of histopathological regression of CIN2/3 to CIN1 or no disease. It also demonstrated clearance of HPV in conjunction with regression of cervical lesions. Robust T-cell activity was detected compared to placebo.
The company plans to present top-line results at the 2014 International Society of DNA Vaccines Conference in San Diego on July 23, 2014.
(INO +14.3%) are up on robust volume in early trading.